Overactivation of the kynurenine pathway, particularly IDO, is associated with an unfavorable prognosis in various cancer types, including gastrointestinal cancers, gynecological cancers, hematological malignancies, breast cancer, lung cancer, glioma, melanoma, prostate cancer, and pancreatic cancer. This evidence concerns the gene IDO1 and prostate carcinoma.